TRANSIENT INHIBITION OF GLUCOSE-UPTAKE MIMICS ISCHEMIC PRECONDITIONING BY SALVAGING ISCHEMIC MYOCARDIUM IN THE RABBIT HEART

被引:27
作者
GOTO, M
TSUCHIDA, A
LIU, YG
COHEN, MV
DOWNEY, JM
机构
[1] UNIV SO ALABAMA, COLL MED, DEPT PHYSIOL, MOBILE, AL 36688 USA
[2] UNIV SO ALABAMA, COLL MED, DEPT MED, MOBILE, AL 36688 USA
关键词
ACETATE; ADENOSINE; GLUCOSE; MYOCARDIAL INFARCTION; PROTEIN KINASE C; PYRUVATE;
D O I
10.1016/0022-2828(95)90011-X
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The aim of this study was to test whether transient inhibition of glucose uptake could precondition the rabbit heart. Rabbit hearts experienced 30 min regional ischemia followed by either 120 min (isolated heart protocol) or 180 min (in situ protocol) reperfusion. Infarct size was determined by tetrazolium staining. In isolated heart experiments, 15 min perfusion with glucose-free Krebs buffer starting 30 min prior to ischemia significantly limited infarct size to 9.9 +/- 2.6% of the risk zone as compared with 29.4 +/- 1.7% infarction in controls. This protection could be blocked (30.8 +/- 3.4%) by polymyxin B (50 mu M), a protein kinase C inhibitor, but not by 8-(p-sulfophenyl)theophylline, an adenosine receptor inhibitor, suggesting the mechanism was similar to that of ischemic preconditioning but without involvement of adenosine receptors. Pyruvate and acetate inhibit glucose uptake without incurring a metabolic deficit. When 20 mM pyruvate or 1 mM acetate was added to the glucose-containing buffer for 15 min prior to ischemia, protection was evident (12.0 +/- 3.0% and 10.0 +/- 3.7% infarction, respectively). However, when acetate (1 mM) was present in the perfusate throughout the experiment, neither omission of glucose nor addition of pyruvate caused protection (26.1 +/- 2.2% and 28.9 +/- 4.7% infarction, respectively). Furthermore, when in situ hearts which preferably utilize lipid substrates were treated with pyruvate (2 g/kg i.v. 20 min before ischemia), infarct size was 40.3 +/- 3.0%, which did not differ from that in untreated hearts (38.6 +/- 3.2%). Hence transient inhibition of glucose uptake can precondition the heart, but only if other substrates which are utilized in preference to glucose are absent. (C) 1995 Academic Press Limited
引用
收藏
页码:1883 / 1894
页数:12
相关论文
共 46 条
[31]   HYPOXIC PRECONDITIONING OF ISCHEMIC CANINE MYOCARDIUM [J].
SHIZUKUDA, Y ;
MALLET, RT ;
LEE, SC ;
DOWNEY, HF .
CARDIOVASCULAR RESEARCH, 1992, 26 (05) :534-542
[32]   CATECHOLAMINES CAN INDUCE ADENOSINE RECEPTOR-MEDIATED PROTECTION OF THE MYOCARDIUM BUT DO NOT PARTICIPATE IN ISCHEMIC PRECONDITIONING IN THE RABBIT [J].
THORNTON, JD ;
DALY, JF ;
COHEN, MV ;
YANG, XM ;
DOWNEY, JM .
CIRCULATION RESEARCH, 1993, 73 (04) :649-655
[33]   PRETREATMENT WITH PERTUSSIS TOXIN BLOCKS THE PROTECTIVE EFFECTS OF PRECONDITIONING - EVIDENCE FOR A G-PROTEIN MECHANISM [J].
THORNTON, JD ;
LIU, GS ;
DOWNEY, JM .
JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY, 1993, 25 (03) :311-320
[34]   INTRACELLULAR CA-2+ AND PROTEIN-KINASE-C MODULATE K+ CURRENT IN GUINEA-PIG HEART-CELLS [J].
TOHSE, N ;
KAMEYAMA, M ;
IRISAWA, H .
AMERICAN JOURNAL OF PHYSIOLOGY, 1987, 253 (05) :H1321-H1324
[35]   LIMITATION OF INFARCT SIZE IN THE RABBIT BY ISCHEMIC PRECONDITIONING IS REVERSIBLE WITH GLIBENCLAMIDE [J].
TOOMBS, CF ;
MOORE, TL ;
SHEBUSKI, RJ .
CARDIOVASCULAR RESEARCH, 1993, 27 (04) :617-622
[36]   ROLE OF ADENOSINE RECEPTOR ACTIVATION IN MYOCARDIAL INFARCT SIZE LIMITATION BY ISCHEMIC PRECONDITIONING [J].
TSUCHIDA, A ;
MIURA, T ;
MIKI, T ;
SHIMAMOTO, K ;
IIMURA, O .
CARDIOVASCULAR RESEARCH, 1992, 26 (05) :456-461
[37]   ALPHA(1)-ADRENERGIC AGONISTS PRECONDITION RABBIT ISCHEMIC MYOCARDIUM INDEPENDENT OF ADENOSINE BY DIRECT ACTIVATION OF PROTEIN-KINASE-C [J].
TSUCHIDA, A ;
LIU, YG ;
LIU, GS ;
COHEN, MV ;
DOWNEY, JM .
CIRCULATION RESEARCH, 1994, 75 (03) :576-585
[38]  
VANWINKLE DM, 1991, CORONARY ARTERY DIS, V2, P613
[39]   TRANSIENT ISCHEMIA INDUCED BY RAPID CARDIAC PACING RESULTS IN MYOCARDIAL PRECONDITIONING [J].
VEGH, A ;
SZEKERES, L ;
PARRATT, JR .
CARDIOVASCULAR RESEARCH, 1991, 25 (12) :1051-1053
[40]  
WALL TM, 1994, J PHARMACOL EXP THER, V270, P681